Citigroup’s Ovid Therapeutics OVID Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $254K | Buy |
114,242
+109,521
| +2,320% | +$196K | ﹤0.01% | 3895 |
|
|
2025
Q4 | $7.7K | Buy |
4,721
+3,913
| +484% | +$6.03K | ﹤0.01% | 5133 |
|
|
2025
Q3 | $1.05K | Sell |
808
-10,603
| -93% | -$9.19K | ﹤0.01% | 5617 |
|
|
2025
Q2 | $3.77K | Sell |
11,411
-31,786
| -74% | -$9.58K | ﹤0.01% | 5312 |
|
|
2025
Q1 | $13.5K | Sell |
43,197
-5,354
| -11% | -$3.29K | ﹤0.01% | 5150 |
|
|
2024
Q4 | $45.3K | Buy |
48,551
+4,599
| +10% | +$5.15K | ﹤0.01% | 5111 |
|
|
2024
Q3 | $51.9K | Buy |
43,952
+29,636
| +207% | +$31K | ﹤0.01% | 5013 |
|
|
2024
Q2 | $11K | Buy |
14,316
+2,864
| +25% | +$7.97K | ﹤0.01% | 5118 |
|
|
2024
Q1 | $34.9K | Buy |
11,452
+1,426
| +14% | +$4.77K | ﹤0.01% | 4810 |
|
|
2023
Q4 | $32.3K | Buy |
10,026
+9,997
| +34,472% | +$34.2K | ﹤0.01% | 4749 |
|
|
2023
Q3 | $111 | Sell |
29
-17,729
| -100% | -$63.7K | ﹤0.01% | 5394 |
|
|
2023
Q2 | $58.2K | Buy |
+17,758
| New | +$60.3K | ﹤0.01% | 4551 |
|
|
2023
Q1 | – | Sell |
-1,237
| Closed | -$2.3K | – | 5755 |
|
|
2022
Q4 | $2.3K | Buy |
1,237
+43
| +4% | +$73 | ﹤0.01% | 5198 |
|
|
2022
Q3 | $2K | Sell |
1,194
-238
| -17% | -$498 | ﹤0.01% | 5516 |
|
|
2022
Q2 | $3K | Sell |
1,432
-239
| -14% | -$578 | ﹤0.01% | 5789 |
|
|
2022
Q1 | $5K | Sell |
1,671
-387
| -19% | -$1.22K | ﹤0.01% | 5826 |
|
|
2021
Q4 | $7K | Sell |
2,058
-1,497
| -42% | -$5.13K | ﹤0.01% | 5624 |
|
|
2021
Q3 | $12K | Sell |
3,555
-556
| -14% | -$2.03K | ﹤0.01% | 5422 |
|
|
2021
Q2 | $16K | Sell |
4,111
-250
| -6% | -$987 | ﹤0.01% | 5429 |
|
|
2021
Q1 | $18K | Sell |
4,361
-6,146
| -58% | -$20.4K | ﹤0.01% | 5320 |
|
|
2020
Q4 | $24K | Buy |
10,507
+4,195
| +66% | +$19.6K | ﹤0.01% | 6531 |
|
|
2020
Q3 | $36K | Buy |
6,312
+479
| +8% | +$3.21K | ﹤0.01% | 5799 |
|
|
2020
Q2 | $43K | Buy |
5,833
+720
| +14% | +$3.37K | ﹤0.01% | 6113 |
|
|
2020
Q1 | $15K | Sell |
5,113
-496,349
| -99% | -$1.67M | ﹤0.01% | 6863 |
|
|
2019
Q4 | $2.08M | Buy |
501,462
+499,976
| +33,646% | +$1.58M | ﹤0.01% | 2921 |
|
|
2019
Q3 | $5K | Sell |
1,486
-499
| -25% | -$1.13K | ﹤0.01% | 7338 |
|
|
2019
Q2 | $4K | Sell |
1,985
-1,519
| -43% | -$2.71K | ﹤0.01% | 7534 |
|
|
2019
Q1 | $7K | Buy |
3,504
+24
| +0.7% | +$60 | ﹤0.01% | 7344 |
|
|
2018
Q4 | $9K | Sell |
3,480
-135
| -4% | -$616 | ﹤0.01% | 7201 |
|
|
2018
Q3 | $20K | Buy |
+3,615
| New | +$27.4K | ﹤0.01% | 7091 |
|
|
2018
Q2 | – | Sell |
-1,522
| Closed | -$10K | – | 7694 |
|
|
2018
Q1 | $10K | Buy |
1,522
+1,009
| +197% | +$8.16K | ﹤0.01% | 7057 |
|
|
2017
Q4 | $5K | Buy |
+513
| New | +$4.71K | ﹤0.01% | 7232 |
|
|
2017
Q3 | – | Sell |
-28,629
| Closed | -$301K | – | 7392 |
|
|
2017
Q2 | $301K | Buy |
+28,629
| New | +$374K | ﹤0.01% | 4450 |
|
Other funds holding OVID
RCM
AAA
EAM
VCM
ACM
SVCM
Citigroup's OVID Position: Q1 2026 in Review
Citigroup increased its Ovid Therapeutics (OVID) stake by 2,320% in Q1 2026, buying an estimated $196K and bringing the position to 114,242 shares worth $254K. The position accounts for ﹤0.01% of the portfolio, ranked #3895.
Citigroup first reported a position in OVID in Q2 2017 and has held it in 33 quarters since. The position peaked at $2.08M in Q4 2019. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.
- Citigroup held 114,242 shares of Ovid Therapeutics worth $254K as of Q1 2026.
- Citigroup bought 109,521 Ovid Therapeutics shares in Q1 2026, an estimated $196K.
- Ovid Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3895 holding.
- Citigroup first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 33 quarters since.
- Citigroup's Ovid Therapeutics position peaked at $2.08M in Q4 2019.
- 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.